Abstract Number: 2478 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital
Background/Purpose: The classification criteria for spondyloarthritis (SpA) intend to identify patients with this disease from the initial stages. The nonspecific characteristics, symptoms, signs, and additional…Abstract Number: 528 • 2013 ACR/ARHP Annual Meeting
Upregulated Th17 and Innate Pathways Are More Characteristic Of The Skin Than The Synovium In Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. There is little understanding of the relative levels of cytokines and chemokines between…Abstract Number: 2486 • 2013 ACR/ARHP Annual Meeting
Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers
Background/Purpose: About 5% of the Brazilian population has some chronic inflammatory arthropathy (CIA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PA) and juvenile…Abstract Number: 344 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
Background/Purpose: Arthritis mutilans (AM), a severe form of psoriatic arthritis (PsA), is characterised clinically by digital shortening resulting from osteolysis and/or erosions. It is still…Abstract Number: 1348 • 2012 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic Arthritis
Background/Purpose: Spondylitis in Psoriatic Arthritis (PsA) sometimes resembles DISH because of the presence of juxta-vertebral calcification that resemble syndesmophytes. Distinguishing spondylitis from DISH has therapeutic…Abstract Number: 1044 • 2012 ACR/ARHP Annual Meeting
Ultrasound Scores of Enthesitis and Dactylitis Do Not Correlate with Corresponding Clinical Findings in Psoriasis Arthritis
Background/Purpose: To compare sonography verified inflammation of entheses, tendons and joints with corresponding clinical findings in psoriasis arthritis (PsA) patients. Methods: Prospective study of 70 consecutive…Abstract Number: 1002 • 2012 ACR/ARHP Annual Meeting
Microrna Expression Profiles in Peripheral Blood Mononuclear Cells of Early Onset Psoriatic Arthritis
Background/Purpose: Micro-RNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression. It is known that an altered miRNA expression plays an important role in…Abstract Number: 573 • 2012 ACR/ARHP Annual Meeting
Differential Association Between Human Leukocyte Antigen (HLA) Alleles and Joint Subluxation and Ankylosis in Patients with Psoriatic Arthritis
Background/Purpose: We have previously reported the association between HLA and KIR gene variants with the development of Arthritis Mutilans (AM) in psoriatic arthritis (PsA). However,…Abstract Number: 2611 • 2012 ACR/ARHP Annual Meeting
Do Patients with Psoriatic Arthritis Fall Into Distinct Clinical Sub-Groups- a Cluster Analysis?
Background/Purpose: To determine if demographic and disease characteristics of patients with PsA at presentation to a PsA clinic cluster into distinct groups. Methods: 1058 patients…Abstract Number: 581 • 2012 ACR/ARHP Annual Meeting
Examining a Role for Th17 Regulation and Toll-Like Receptor Signaling in Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis that develops in 30% of patients with cutaneous psoriasis (PsC). Joint inflammation in PsA is mediated…Abstract Number: 2557 • 2012 ACR/ARHP Annual Meeting
Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: Results of a Phase 3, multicenter, double-blind, placebo-controlled studyBackground/Purpose: Assess efficacy & safety…Abstract Number: 590 • 2012 ACR/ARHP Annual Meeting
The Association Between KIR3DL1 Alleles and Psoriatic Arthritis
Background/Purpose: Killer-cell immunoglobulin-like receptors (KIRs) are activating and inhibitory receptors that regulate NK and NK-T cells, which have been found in psoriatic plaques and synovial…Abstract Number: 2558 • 2012 ACR/ARHP Annual Meeting
Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry
Background/Purpose: Treatment with tumor-necrosis-factor-alpha inhibitors (TNFi) has improved the outcome in patients with psoriatic arthritis (PsA) who have failed treatment with synthetic disease modifying antirheumatic…Abstract Number: 552 • 2012 ACR/ARHP Annual Meeting
Simple Questions in the Dermatology Office May Reasonably Exclude, but Do Not Reliably Identify Psoriatic Arthritis Patients: Results From the Center of Excellence for Psoriasis and Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) affects between 10-30% of patients with psoriasis (PsO), but is often missed when assessed in a dermatology clinic. The Center of…Abstract Number: 2560 • 2012 ACR/ARHP Annual Meeting
Response and Drug Survival of 1st TNF-Inhibitor in 440 Patients with Psoriatic Arthritis – What Is the Role of Co-Medication with Methotrexate?
Background/Purpose: It is well established that methotrexate (MTX) co-medication improves efficacy of TNF-inhibitors (TNFi) in rheumatoid arthritis, while in ankylosing spondylitis it is widely accepted…